ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued U.S. Patent 11147067 (the ‘067 patent) titled, “Method And System For Monitoring Tissue Temperature” from the United States Patent & Trademark Office.
The ‘067 patent relates to a novel method and system for monitoring tissue temperature during surgical procedures using ENDRA’s TAEUS® system. ENDRA expects that TAEUS® will be effective for both thermotherapy and cryotherapy procedures. The recently issued patent complements U.S. Patent 10631734, also titled, “Method And System For Monitoring Tissue Temperature,” which was issued on April 28, 2020. Each of these patents utilize different methods to achieve similar results.
“The issuance of this new patent represents the continued advancement of the development of our optimized ultrasound and thermoacoustic imaging systems for a wide variety of applications where no practical tools currently exist, including for Non-Alcoholic Fatty Liver Disease (NAFLD)," explained ENDRA's Chief Executive Officer Francois Michelon. "Our IP portfolio continues to grow and currently stands at 87 assets, which we define as patents issued, filed or in preparation. As we advance TAEUS® commercial launch plans for Europe and await U.S. regulatory response, it is essential to protect our intellectual property in priority global markets.”
TAEUS® is currently cleared for sale in countries that recognize the CE mark, including those in the European Union, and a 510(k) application has been submitted to the U.S. Food and Drug Administration.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. Examples of forward-looking statements for ENDRA include, among others, estimates of the timing of future events and achievements, such as the expectations regarding the transition of leadership of ENDRA’s finance function, and expectations concerning ENDRA's business strategy, which may be affected by risks related to the impact of COVID-19 on its business plan, its ability to find and maintain development partners, market acceptance of its technology and the amount and nature of competition in its industry, its ability to protect its intellectual property, and other risks and uncertainties described in its filings with the Securities and Exchange Commission. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others, our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; the impact of COVID-19 on our business plans; our ability to find and maintain development partners, market acceptance of our technology and the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in ENDRA's filings with the Securities and Exchange Commission. The forward-looking statements made in this news release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.